1st Edition

Novel Therapeutic Agents for the Treatment of Autoimmune Diseases

    Provides a detailed survey of therapies for autoimmune diseases, exploring the rationale for their use and clinical data regarding their potential benefit.


    The Evaluation of Biological Agents, Vibeke Strand and David L. Scott

    Cellular Targeted Therapies

    Anti-CD5 Ricin A Chain Immunoconjugate Therapy in Rheumatoid Arthritis, John J. Cash
    Early Clinical Studies of IL-2 Fusion Toxin in Patients with Severe Rheumatoid Arthritis

    Recent-Onset Insulin-Dependent Diabetes Mellitus, and Psoriasis, Thasia G. Woodworth and Karen Parker
    Chimeric Anti-CD4 Antibody as a Potential Therapeutic Agent for Rheumatoid Arthritis, Larry W. Moreland and William J. Koopman
    CD4 Monoclonal Antibody Therapy in Rheumatoid Arthritis, F. C. Breedveld
    The Use of CE9.1, a Primatized Monoclonal Anti-CD4, in the Treatment of Rheumatoid Arthritis, David E. Yocum, Alan M. Solinger, and John Lipani
    CAMPATH-1H Therapy in Autoimmune Diseases, Richard A. Watts and John D. Isaacs
    CAMPATH-1H in Rheumatoid Arthritis: United States Experience, David E. Yocum and Jeffrey M. Johnston

    Cytokine Targeted Therapies

    Interferon-Gamma in the Treatment of Rheumatoid Arthritis, Eric M. Veys, Herman Mielants, and Gust Verbruggen
    Tumor Necrosis Factor Blockade in Rheumatoid Arthritis, Michael J. Elliott, Marc Feldmann, and Ravinder N. Maini
    Engineered Human Anti-Tumor Necrosis Factor-Alpha (TNFaAntibody, CDP571, in Rheumatoid Arthritis, Ernest H. S. Choy and Gabriel S. Panayi
    Clinical Experience with Recombinant Human Interleukin-1 Receptor Type I (Rhu IL-1RI) in Patients with Rheumatoid Arthritis, Richard M. Pope, Barbara Drevlow, Jennifer Capezio, Rosa Lovis, and Alan Landay
    Treatment of Rheumatoid Arthritis with Soluble Tumor Necrosis Factor Receptor, Gary R. Margolies, William J. Koopman, and Larry W. Moreland

    Adhesion Molecule Targeted Therapies

    Treatment of Rheumatoid Arthritis with a Monoclonal Antibody to Intercellular Adhesion Molecule-1, Arthur F. Kavanaugh and Peter E. Lipsky

    Potential Antigen-Specific Therapies

    T-Cell-Receptor Peptide Therapy for Multiple Sclerosis, Arthur A. Vanderbark, Dennis N. Bourdette, Ruth H. Whitham, and Halina Offner
    T-Cell Receptor Peptide Vaccination Studies in Rheumatoid Arthritis, Louis W. Heck, Larry W. Moreland, and William J. Koopman
    Oral Tolerance for the Treatment of Autoimmune Disease, David A Hafler and Howard L. Weiner
    Oral Tolerance, David E. Trentham
    Intravenous Immunoglobulin (IVIg) in the Treatment of Autoimmune Diseases, Vibeke Strand and Martin L. Lee

    Purine and Pyrimidine Synthesis Inhibitors

    Inhibitors of De Novo Nucleotide Synthesis in the Treatment of Rheumatoid Arthritis, Robert I. Fox and Randall E. Morris
    Leflunomide: A New Immunosuppressive Drug, David L. Scott and Vibeke Strand

    Future Directions

    An Assessment of Novel Agents in the Treatment of the Rheumatic Diseases, Vibeke Strand and Lee S. Simon


    Vibeke Strand, David L. Scot, Lee S. Simon